{"id":22313,"date":"2022-03-28T08:25:47","date_gmt":"2022-03-28T08:25:47","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=88975"},"modified":"2022-03-28T08:25:47","modified_gmt":"2022-03-28T08:25:47","slug":"taiho-pharmaceutical-obtains-approval-to-manufacture-and-market-nk1-receptor-antagonist-arokaris-i-v-infusion-235mg-in-japan","status":"publish","type":"post","link":"https:\/\/myanmarnewswire.com\/taiho-pharmaceutical-obtains-approval-to-manufacture-and-market-nk1-receptor-antagonist-arokaris-i-v-infusion-235mg-in-japan\/","title":{"rendered":"Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris\u00ae I.V. Infusion 235mg in Japan"},"content":{"rendered":"
Taiho Pharmaceutical Obtains Approval <\/strong>to Manufacture and Market NK<\/strong>1<\/strong><\/sub> Receptor Antagonist <\/strong>Arokaris<\/strong>\u00ae<\/strong><\/sup> I.V. Infusion 235mg in Japan<\/strong><\/p>\n Tokyo, Japan<\/strong>, <\/strong>and <\/strong>Lugano, Switzerland<\/strong> March<\/strong> 28<\/strong>,<\/strong> 202<\/strong>2<\/strong> –<\/strong> Taiho Pharmaceutical Co., Ltd. (hereinafter \u201cTaiho\u201d) and Helsinn Group (hereinafter \u201cHelsinn\u201d), announced today that Taiho has been granted approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market the NK1<\/sub> receptor antagonist antiemetic drug \u201cArokaris\u00ae<\/sup> I.V. Infusion 235mg\u201d (generic name: fosnetupitant chloride hydrochloride) for gastrointestinal symptoms (nausea and vomiting, including delayed phase) associated with cancer chemotherapy (cisplatin, etc.).<\/p>\n Arokaris\u00ae<\/sup> is an NK1<\/sub> receptor antagonist antiemetic drug and is a phosphorylated pro-drug preparation (injection) which is converted to netupitant, the active component. Chemotherapy-induced nausea and vomiting can have deleterious effects on patients\u2019 quality-of-life, and may also interfere with chemotherapy administration, therefore guidelines1-4<\/sup> recommend adequate prophylaxis.<\/p>\n Taiho, which acquired exclusive development and marketing rights for Arokaris\u00ae<\/sup> in Japan under a license agreement with Helsinn in April 2011, has conducted clinical trials in Japan since then, and submitted a new drug application in March 2021.5<\/sup><\/p>\n This approval is based on the results of a Phase III clinical study (CONSOLE6<\/sup>) comparing the efficacy and safety of Arokaris\u00ae<\/sup> versus fosaprepitant in patients receiving highly emetogenic chemotherapy in combination with palonosetron and dexamethasone. The results of this study were published in the Journal of Clinical Oncology<\/em>.7<\/sup><\/p>\n Within Taiho\u2019s mainstay field of oncology, the company is also focusing on cancer supportive care. Under a former distribution and license agreement with Helsinn, effective as of January 2004, Taiho has been marketing the 5-HT3<\/sub> receptor antagonist Aloxi\u00ae<\/sup> (generic name: palonosetron hydrochloride) in Japan since April 2010.<\/p>\n Helsinn is pleased to be able to bring this new treatment option for supportive care in cancer to patients in Japan. Taiho will promote the proper use of Arokaris\u00ae<\/sup> to ensure that it can make further contributions to patients and healthcare professionals.<\/p>\n Product Information<\/strong><\/p>\n
\n<\/strong><\/p>\n